Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
AVR · against 471 other Healthcare companies of similar size
Ranked #304 of 472 · scores higher than 12% of peers
Bars: peers in each 10-point band of the valuation score169 peers with a valuation score of 0–9, including AVR · Click a bar to see the companies
Mainly because of its earnings yield, EBITDA yield and free cash flow yield, which are weaker than most Healthcare peers.
| Metric | AVR | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 458 reported | -34.8% | 0.5% | 5% | 30% | |
| EBITDA yieldHigher is better · 477 reported | -35.7% | 3.5% | 8% | 50% | |
| Free cash flow yieldHigher is better · 203 reported | -16.2% | -5.5% | 29% | 20% | |
| Book yieldHigher is better · 468 reported | 46.1% | 47.5% | 49% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 3.5B HKD (≈$451M) | 99 | 51 | |
| 1 | 2.9B HKD (≈$365M) | 99 | 84 | |
| 1 | 89.9B JPY (≈$611M) | 99 | 68 | |
| 1 | 3.1B HKD (≈$396M) | 99 | 61 | |
| 1 | 6.50T IDR (≈$403M) | 99 | 69 | |
| 304 | 782M USD | 8 | 35 | |
| 304 | 647M USD | 8 | 40 | |
| 304 | 377M USD | 8 | 29 | |
| 304 | 334M USD | 8 | 36 | |
| 304 | 546M USD | 8 | 31 | |
| 304 | 815M USD | 8 | 53 | |
| 304 | 593M USD | 8 | 40 | |
| 304 | 293M USD | 8 | ||
| 304 | 675M USD | 8 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score